MicroPort Scientific Executive and Leadership Team

Martin Sun, the Chief Financial Officer at MicroPort Scientific, manages the global financial health and capital allocation strategies for the organization. Sun oversees fiscal planning, investor relations, and the optimization of capital structures to support long-term expansion. By monitoring market trends, the Chief Financial Officer ensures that resource distribution aligns with the company's mission of providing high-quality medical treatments. This leadership role involves coordinating with the Board to maintain transparency and financial stability across international operations. Martin Sun directs the budgeting processes for research initiatives, ensuring that capital flows toward high-impact medical device projects. Through rigorous financial oversight, the Chief Financial Officer mitigates operational risks while maximizing shareholder value. Sun maintains a focus on sustainable growth, ensuring that the financial foundation supports the ongoing development of innovative healthcare solutions that improve patient lives on a global scale.

YiYong Sun, the President at MicroPort Scientific, directs the overarching operational strategy and business development initiatives for the company's cardiovascular division. Sun oversees the execution of market expansion plans, ensuring that high-quality medical devices reach healthcare providers across diverse international territories. By coordinating cross-functional teams, the President ensures that product delivery remains efficient and compliant with regional regulatory requirements. This leadership role involves managing key partnerships with hospitals and medical institutions to broaden the reach of life-extending treatments. YiYong Sun drives the implementation of operational excellence programs, focusing on streamlining supply chain logistics to support rapid market growth. Through the alignment of business objectives with clinical needs, the President ensures that the company maintains its reputation for excellence. Sun monitors performance metrics to optimize regional operations, ensuring that the organization consistently delivers superior value to patients and healthcare systems globally.

Caesar Fonte, the President at MicroPort Scientific, directs the strategic growth and commercial operations for the company's orthopedic and joint replacement business units. Fonte oversees the development of sales channels and the implementation of market-specific strategies to increase the adoption of advanced medical devices. By managing relationships with key opinion leaders in the medical community, the President ensures that product offerings meet the specific needs of surgeons and patients. This leadership role involves driving the commercialization of new technologies, ensuring that innovative solutions are effectively integrated into clinical practice. Caesar Fonte directs the expansion of the company's footprint in emerging markets, focusing on building robust distribution networks. Through the optimization of commercial processes, the President supports the company's mission of improving patient quality of life. Fonte maintains a focus on operational efficiency, ensuring that the business units achieve sustainable growth while upholding the highest standards of medical care.

Philippe Wanstok, the President at MicroPort Scientific, directs the global commercial strategy and market penetration efforts for the company's neurovascular and electrophysiology product lines. Wanstok oversees the alignment of sales and marketing initiatives to ensure that advanced medical devices are accessible to healthcare providers in major international markets. By leading the commercial teams, the President ensures that the company's innovative solutions effectively address complex clinical challenges. This leadership role involves coordinating with regional managers to adapt business models to local healthcare environments. Philippe Wanstok directs the development of strategic alliances that enhance the company's presence in the global medical device sector. Through the implementation of data-driven sales strategies, the President drives revenue growth and market share expansion. Wanstok maintains a focus on delivering high-quality medical treatments, ensuring that the company's commercial activities directly contribute to the overarching mission of extending and improving patient lives.

Qiyi Luo, the Chief Technology Officer at MicroPort Scientific, directs the research and development of advanced medical device platforms. Luo oversees the engineering teams responsible for creating minimally invasive surgical tools and cardiovascular implants. By prioritizing technical excellence, the Chief Technology Officer ensures that all product designs meet rigorous international safety standards. This leadership role involves constant collaboration with clinical researchers to translate complex medical needs into scalable manufacturing processes. Qiyi Luo maintains a focus on integrating digital health technologies into existing product lines to enhance patient outcomes across global markets. Through the implementation of cutting-edge materials science, the Chief Technology Officer accelerates the development cycle for next-generation therapeutic solutions. Luo drives the technical roadmap, ensuring that the company remains at the forefront of the medical device industry while maintaining a competitive edge in high-growth regions.

Tao Li, the Co-Founder & Chief Technology Officer at MicroPort Scientific, architects the foundational technological vision for the company's diverse medical device portfolio. Li oversees the long-term innovation strategy, focusing on the integration of proprietary technologies into complex surgical systems. By guiding the technical direction, the Co-Founder & Chief Technology Officer ensures that the company maintains its commitment to high-quality medical treatments. This leadership role involves fostering a culture of invention and scientific rigor across all engineering departments. Tao Li directs the exploration of emerging medical fields, identifying opportunities for technological breakthroughs that address unmet patient needs. Through strategic oversight of intellectual property and patent development, the Co-Founder & Chief Technology Officer secures the company's market position. Li drives the evolution of the product pipeline, ensuring that every innovation aligns with the core mission of enabling longer and healthier lives for patients worldwide.